Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 19/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 17/20 | 1.00 |
| ▸ | ALDH2 | P05091 | 5/20 | 0.76 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589642 | 0.99 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2CHRM5 | |
| Bromide SCHEMBL22589413 | 0.87 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2 | |
| Bromide SCHEMBL22589394 | 0.86 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2CHRM5 | |
| Bromide SCHEMBL31748970 | 0.86 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2CHRM5 | |
| Bromide SCHEMBL22589414 | 0.86 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL22589390 | 0.86 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL22589400 | 0.85 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2CHRM5 | |
| SCHEMBL22589198 | 0.85 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2 | |
| Bromide SCHEMBL22589428 | 0.83 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2 | |
| Bromide SCHEMBL31748988 | 0.83 | ALDH3A1 (1.00) | ALDH3A1ALDH1A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616678-B2 | Methods to of aldehyde dehydrogenases for treatment of cancer | THE PENN STATE RESEARCH FOUNDATION (PA) | 2026-05-05 | — | — | US | claimed |
| US-20250387367-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | PENN STATE RES FOUND (US) | 2025-12-25 | — | — | US | claimed |
| US-20230301965-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| US-20220175723-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION | 2022-06-09 | — | — | US | claimed |
| EP-3958868-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2022-03-02 | — | — | EP | claimed |
| WO-2021252749-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-12-16 | — | — | WO | claimed |
| WO-2020219531-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2020-10-29 | — | — | WO | claimed |
| US-12616678-B2 | Methods to of aldehyde dehydrogenases for treatment of cancer | THE PENN STATE RESEARCH FOUNDATION (PA) | 2026-05-05 | — | — | US | disclosed |
| US-20250387367-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | PENN STATE RES FOUND (US) | 2025-12-25 | — | — | US | disclosed |
| US-20230301965-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| US-20220175723-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION | 2022-06-09 | — | — | US | disclosed |
| EP-3958868-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2021252749-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2020219531-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387367-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | ALDH3A1, ALDH2, ADH1C | ALDH3A1 1/4885ALDH1A1 4/4885ALDH2 2/4885 |
| US-20220175723-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | DPYD, ALDH2, DLD | ALDH3A1 4/4885ALDH1A1 6/4885ALDH2 2/4885 |
| US-12616678-B2 | Methods to of aldehyde dehydrogenases for treatment of cancer | ALDH1A1, ALDH3A1, ADH1C | ALDH3A1 2/4885ALDH1A1 1/4885ALDH2 4/4885 |
| US-20230301965-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | DPYD, ALDH2, DLD | ALDH3A1 4/4885ALDH1A1 6/4885ALDH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.